Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach

International Journal of Medical Sciences

Volumn 7, Issue 2, 2010, Pages 94-100

  Katsakiori, Paraskevi F ^a   Papapetrou, Eirini P ^b   Sakellaropoulos, George C ^a   Goumenos, Dimitrios S ^a   Nikiforidis, George C ^a   Flordellis, Christodoulos S ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CYP3A5; General linear models; Linear regression; Renal transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYTOCHROME P450 3A5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HOMOZYGOTE; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LIVER FUNCTION; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ALLELE; BLOOD; DRUG EFFECT; KIDNEY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MIDDLE AGED;

ADULT; ALLELES; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STEROIDS; TACROLIMUS;

EID: 77954897678     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.7.94     Document Type: Article

References (23)

1. Fredericks S, Holt DW. Pharmacogenomics of immunosup pressive drug metabolism. Curr Opin Nephrol Hypertens. 2003; 12: 607-13.
2. MacPhee IA, Fredericks S, Tai T, et al. The influence of phar macogenetics on the time to achieve target tacrolimus concen trations after kidney transplantation. Am J Transplant. 2004; 4: 914-9.
3. Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation. 2008 Apr 15; 85 (Suppl 7): S19-24.
4. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacoki netic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003; 118: 2409-14.
5. de Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev. (Orland) 2008; 22(1): 6-20.
6. Evans WE. Pharmacogenomics: marshalling the human ge nome to individualise drug therapy. Gut. 2003; 52 (Suppl 2): S10-S18.
7. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004; 14: 147-54.
8. Brockmöller J, Tzvetkov MV. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol. 2008 Feb; 64: 133-57.
9. Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S, Haschke M. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2006; 28: 39-44.
10. Daly AK. Significance of the minor cytochrome P450 3A iso forms. Clin Pharmacokinet. 2006; 45: 13-31.
11. MacPhee IA, Holt DW. A pharmacogenetic strategy for im munosuppression based on the CYP3A5 genotype. Transplan tation. 2008; 85: 163-5.
12. Arvanitidis K, Ragia G, Iordanidou M, et al. Genetic polymor phisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007; 21: 419-26.
13. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005; 79: 499-502.
14. Zhao Y, Song M, Guan D, et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and ta crolimus. Transplant Proc. 2005; 37: 178-81.
15. McCarthy AD, Kennedy JL, Middleton LT. Pharmacogenetics in drug development. Philos Trans R Soc Lond B Biol Sci. 2005; 360: 1579-88.
16. Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug develop ment. Br J Clin Pharmacol. 2004; 58: 601-8.
17. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004; 78: 1182-7.
18. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003; 74: 245-54.
19. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002; 48: 1668-71.
20. Roy JN, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymor phisms in different ethnic populations. Drug Metab Dispos. 2005 Jul; 33: 884-7.
21. Tirelli S, Ferraresso M, Ghio L, et al. The effect of CYP3A5 po lymorphisms on the pharmacokinetics of tacrolimus in adoles cent kidney transplant recipients. Med Sci Monit. 2008; 14: CR251-4.
22. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Phy sician. 2007; 76: 391-6.
23. Anglicheau D, Legendre C, Thervet E. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from re trospective analyses to prospective studies. Transplant Proc. 2007; 39: 2142-4.